Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial,
2022,
J.S. Frenel ,
J.W. Kim ,
N. Aryal ,
R. Asher ,
D. Berton ,
L. Vidal ,
et al. ,
Tomasz Huzarski(*) ,
S. Pignata ,
N. Colombo ,
Annals of Oncology, Vol. 33, Issue 10, 1021--1028, ISSN: 0923-7534, eISSN: 1569-8041,
bibliogr.
summ.
Słowa kluczowe: BRCA mutation, PARP inhibitor resistance, relapsing ovarian cancer
Kod: CZR-N-WYKAZ
BibTeX
(pkt. 200)
DOI: 10.1016/j.annonc.2022.06.011